Anti-Neuroinflammatory Cannabinoid Acids as a New Therapeutic Approach for Multiple Sclerosis
Molecules · 07.04.2026 · 31 (7) · 1227
DOI: 10.3390/molecules31071227 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 07.04.2026. Verfasst von Nitsan Sharon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beer-Sheva P.O. Box 653, Israel. Hauptthemen laut MEDLINE: Cannabinoids, Encephalomyelitis, Autoimmune, Experimental, Multiple Sclerosis, Neuroglia. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Israel Science Foundation.
Abstract (Originalsprache)
Neuroinflammation is a hallmark of multiple sclerosis (MS). MS is marked by glial cell activation, autoreactive T cells, and the release of pro-inflammatory cytokines and free radicals. Current therapeutic strategies aim to modulate the immune response using disease-modifying therapies, to slow disease progression. The specific aims of this study were: (a) to investigate the effect of cannabinoid acids on the release of glial neuroinflammatory mediators, (b) to examine the effect of intraperitoneally administered cannabinoid acids on symptoms of MS, and (c) to evaluate their effects on microglial and astrocyte activation and CD4+ T cell infiltration into the spinal cords of MS mice. Exposure of BV2 microglia to cannabinoid acids attenuated lipopolysaccharide (LPS)-induced expression of inducible nitric oxide synthase by 40–90% it also reduced the release of nitric oxide and interleukin-17A. Among the cannabinoid acids tested, cannabidiolic acid (CBDA) significantly increased tumor necrosis factor alpha (TNFα) secretion by up to 40% in LPS-stimulated BV2 cells. Intraperitoneal administration of CBDA also resulted in a twofold increase in TNFα secretion in splenocytes isolated from MS mice, compared to untreated MS controls. This study provides evidence that CBDA significantly reduces neurological scores, while both cannabinoid acids attenuate microgliosis, astrogliosis, and CD4+ T cell migration in lumbar spinal cord sections of MS mice. These compounds cross the blood–brain barrier (BBB) and act directly within the central nervous system. The consistent elevation of TNFα in the presence of CBDA across three experimental models suggests a distinctive immunomodulatory role for CBDA, with potential therapeutic implications in MS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beer-Sheva P.O. Box 653, Israel.
- Institute of Soil Water and Environmental Sciences, Volcani Center, Rishon LeZion 15159, Israel.
- Eastern Regional Research and Development Center, Judea Center, Kiryat Arba 90100, Israel.
ORCID-Profile: Nitsan Sharon, Shimon Ben-Shabat, Sigal Fleisher-Berkovich
Förderung
- Israel Science Foundation
Zitieren
APA
Sharon, N., Ventura, Y., Bernstein, N., Gorelick, J., Ben-Shabat, S., & Fleisher-Berkovich, S. (2026). Anti-Neuroinflammatory Cannabinoid Acids as a New Therapeutic Approach for Multiple Sclerosis. Molecules, 31(7), 1227. https://doi.org/10.3390/molecules31071227
Vancouver
Sharon N, Ventura Y, Bernstein N, Gorelick J, Ben-Shabat S, Fleisher-Berkovich S. Anti-Neuroinflammatory Cannabinoid Acids as a New Therapeutic Approach for Multiple Sclerosis. Molecules. 2026;31(7):1227. doi:10.3390/molecules31071227
BibTeX
@article{Sharon2026,
author = {Sharon, Nitsan and Ventura, Yvonne and Bernstein, Nirit and Gorelick, Jonathan and Ben-Shabat, Shimon and Fleisher-Berkovich, Sigal},
title = {Anti-Neuroinflammatory Cannabinoid Acids as a New Therapeutic Approach for Multiple Sclerosis},
journal = {Molecules},
year = {2026},
volume = {31},
number = {7},
pages = {1227},
doi = {10.3390/molecules31071227}
}
EUVIMED